# DRAMMATIC (NCT04071457)

> S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04071457
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: SWOG Cancer Research Network
- Conditions: Multiple Myeloma
- Interventions: Lenalidomide; Daratumumab/rHuPH20
- Enrollment: 1100
- Primary outcome: Overall Survival

## Commentary we found

- X threads: 133
- YouTube: 4
- Podcasts: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=drammatic-nct04071457

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04071457", "email": "<work email>"}; the inbox owner confirms by the emailed link.